Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
Specificity of antinuclear factor testing: what does specific mean?.

Canadian Medical Association journal

Borak J, Vasey F, Lauter S, Dorval G, Osterland CK.
PMID: 20313481
Can Med Assoc J. 1980 Sep 20;123(6):474-6.

No abstract available.

Cite
Borak J, Vasey F, Lauter S, et al. Specificity of antinuclear factor testing: what does specific mean?. Can Med Assoc J. 1980;123(6):474-6
Borak, J., Vasey, F., Lauter, S., Dorval, G., & Osterland, C. K. (1980). Specificity of antinuclear factor testing: what does specific mean?. Canadian Medical Association journal, 123(6), 474-6.
Borak, J, et al. "Specificity of antinuclear factor testing: what does specific mean?." Canadian Medical Association journal vol. 123,6 (1980): 474-6.
Borak J, Vasey F, Lauter S, Dorval G, Osterland CK. Specificity of antinuclear factor testing: what does specific mean?. Can Med Assoc J. 1980 Sep 20;123(6):474-6. PMID: 20313481; PMCID: PMC1704850.
Copy Download .nbib Format: NLM
CHEMICAL CHARACTERIZATION OF GLYCOPEPTIDES FROM HUMAN gammaM-GLOBULINS.

The Journal of experimental medicine

Davie JM, Osterland CK.
PMID: 19867304
J Exp Med. 1968 Oct 01;128(4):699-713. doi: 10.1084/jem.128.4.699.

A survey of human pathological macroglobulins revealed that gammaM can be divided into at least two groups on the basis of carbohydrate composition. Differences between the two groups exist in the total percentage of carbohydrate (10.69 +/- 1.49% for...

Cite
Davie JM, Osterland CK. CHEMICAL CHARACTERIZATION OF GLYCOPEPTIDES FROM HUMAN gammaM-GLOBULINS. J Exp Med. 1968;128(4):699-713doi: 10.1084/jem.128.4.699.
Davie, J. M., & Osterland, C. K. (1968). CHEMICAL CHARACTERIZATION OF GLYCOPEPTIDES FROM HUMAN gammaM-GLOBULINS. The Journal of experimental medicine, 128(4), 699-713. https://doi.org/10.1084/jem.128.4.699
Davie, J M, and Osterland, C K. "CHEMICAL CHARACTERIZATION OF GLYCOPEPTIDES FROM HUMAN gammaM-GLOBULINS." The Journal of experimental medicine vol. 128,4 (1968): 699-713. doi: https://doi.org/10.1084/jem.128.4.699
Davie JM, Osterland CK. CHEMICAL CHARACTERIZATION OF GLYCOPEPTIDES FROM HUMAN gammaM-GLOBULINS. J Exp Med. 1968 Oct 01;128(4):699-713. doi: 10.1084/jem.128.4.699. PMID: 19867304; PMCID: PMC2138547.
Copy Download .nbib Format: NLM
FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study.

EJNMMI research

Mogensen MB, Loft A, Aznar M, Axelsen T, Vainer B, Osterlind K, Kjaer A.
PMID: 28695424
EJNMMI Res. 2017 Dec;7(1):56. doi: 10.1186/s13550-017-0302-3. Epub 2017 Jul 10.

BACKGROUND: Fluoro-L-thymidine (FLT) is a positron emission tomography/computed tomography (PET/CT) tracer which reflects proliferative activity in a cancer lesion. The main objective of this prospective explorative study was to evaluate whether FLT-PET can be used for the early evaluation...

Cite
Mogensen MB, Loft A, Aznar M, et al. FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study. EJNMMI Res. 2017;7(1):56doi: 10.1186/s13550-017-0302-3.
Mogensen, M. B., Loft, A., Aznar, M., Axelsen, T., Vainer, B., Osterlind, K., & Kjaer, A. (2017). FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study. EJNMMI research, 7(1), 56. https://doi.org/10.1186/s13550-017-0302-3
Mogensen, Marie Benzon, et al. "FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study." EJNMMI research vol. 7,1 (2017): 56. doi: https://doi.org/10.1186/s13550-017-0302-3
Mogensen MB, Loft A, Aznar M, Axelsen T, Vainer B, Osterlind K, Kjaer A. FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study. EJNMMI Res. 2017 Dec;7(1):56. doi: 10.1186/s13550-017-0302-3. Epub 2017 Jul 10. PMID: 28695424; PMCID: PMC5503853.
Copy Download .nbib Format: NLM
Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society

Eefsen RL, Engelholm L, Alpizar-Alpizar W, Van den Eynden GG, Vermeulen PB, Christensen IJ, Laerum OD, Rolff HC, Høyer-Hansen G, Vainer B, Osterlind K, Illemann M.
PMID: 26268716
Cancer Microenviron. 2015 Aug;8(2):93-100. doi: 10.1007/s12307-015-0172-z. Epub 2015 Aug 14.

Proteolytic activity and inflammation in the tumour microenvironment affects cancer progression. In colorectal cancer (CRC) liver metastases it has been observed that three different immune profiles are present, as well as proteolytic activity, determined by the expression of urokinase-type...

Cite
Eefsen RL, Engelholm L, Alpizar-Alpizar W, et al. Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy. Cancer Microenviron. 2015;8(2):93-100doi: 10.1007/s12307-015-0172-z.
Eefsen, R. L., Engelholm, L., Alpizar-Alpizar, W., Van den Eynden, G. G., Vermeulen, P. B., Christensen, I. J., Laerum, O. D., Rolff, H. C., Høyer-Hansen, G., Vainer, B., Osterlind, K., & Illemann, M. (2015). Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 8(2), 93-100. https://doi.org/10.1007/s12307-015-0172-z
Eefsen, R L, et al. "Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy." Cancer microenvironment : official journal of the International Cancer Microenvironment Society vol. 8,2 (2015): 93-100. doi: https://doi.org/10.1007/s12307-015-0172-z
Eefsen RL, Engelholm L, Alpizar-Alpizar W, Van den Eynden GG, Vermeulen PB, Christensen IJ, Laerum OD, Rolff HC, Høyer-Hansen G, Vainer B, Osterlind K, Illemann M. Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy. Cancer Microenviron. 2015 Aug;8(2):93-100. doi: 10.1007/s12307-015-0172-z. Epub 2015 Aug 14. PMID: 26268716; PMCID: PMC4542827.
Copy Download .nbib Format: NLM
Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer.

Cancers

Dahlmann M, Monks A, Harris ED, Kobelt D, Osterland M, Khaireddine F, Herrmann P, Kemmner W, Burock S, Walther W, Shoemaker RH, Stein U.
PMID: 35008201
Cancers (Basel). 2021 Dec 22;14(1). doi: 10.3390/cancers14010037.

Metastasis is directly linked to colorectal cancer (CRC) patient survival. Wnt signaling through β-catenin plays a key role. Metastasis-inducing S100A4 is a Wnt/β-catenin target gene and a prognostic biomarker for CRC and other cancer types. We aimed to identify...

Cite
Dahlmann M, Monks A, Harris ED, et al. Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010037.
Dahlmann, M., Monks, A., Harris, E. D., Kobelt, D., Osterland, M., Khaireddine, F., Herrmann, P., Kemmner, W., Burock, S., Walther, W., Shoemaker, R. H., & Stein, U. (2021). Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. Cancers, 14(1), . https://doi.org/10.3390/cancers14010037
Dahlmann, Mathias, et al. "Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010037
Dahlmann M, Monks A, Harris ED, Kobelt D, Osterland M, Khaireddine F, Herrmann P, Kemmner W, Burock S, Walther W, Shoemaker RH, Stein U. Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. Cancers (Basel). 2021 Dec 22;14(1). doi: 10.3390/cancers14010037. PMID: 35008201; PMCID: PMC8750436.
Copy Download .nbib Format: NLM
Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer.

Cancers

Dahlmann M, Monks A, Harris ED, Kobelt D, Osterland M, Khaireddine F, Herrmann P, Kemmner W, Burock S, Walther W, Shoemaker RH, Stein U.
PMID: 35008201
Cancers (Basel). 2021 Dec 22;14(1). doi: 10.3390/cancers14010037.

Metastasis is directly linked to colorectal cancer (CRC) patient survival. Wnt signaling through β-catenin plays a key role. Metastasis-inducing S100A4 is a Wnt/β-catenin target gene and a prognostic biomarker for CRC and other cancer types. We aimed to identify...

Cite
Dahlmann M, Monks A, Harris ED, et al. Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010037.
Dahlmann, M., Monks, A., Harris, E. D., Kobelt, D., Osterland, M., Khaireddine, F., Herrmann, P., Kemmner, W., Burock, S., Walther, W., Shoemaker, R. H., & Stein, U. (2021). Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. Cancers, 14(1), . https://doi.org/10.3390/cancers14010037
Dahlmann, Mathias, et al. "Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010037
Dahlmann M, Monks A, Harris ED, Kobelt D, Osterland M, Khaireddine F, Herrmann P, Kemmner W, Burock S, Walther W, Shoemaker RH, Stein U. Combination of Wnt/β-Catenin Targets S100A4 and DKK1 Improves Prognosis of Human Colorectal Cancer. Cancers (Basel). 2021 Dec 22;14(1). doi: 10.3390/cancers14010037. PMID: 35008201.
Copy Download .nbib Format: NLM
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.

Cancer

Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS.
PMID: 34882781
Cancer. 2021 Dec 09; doi: 10.1002/cncr.34057. Epub 2021 Dec 09.

BACKGROUND: Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study, the authors looked at the experience with EV in...

Cite
Koshkin VS, Henderson N, James M, et al. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2021;doi: 10.1002/cncr.34057.
Koshkin, V. S., Henderson, N., James, M., Natesan, D., Freeman, D., Nizam, A., Su, C. T., Khaki, A. R., Osterman, C. K., Glover, M. J., Chiang, R., Makrakis, D., Talukder, R., Lemke, E., Olsen, T. A., Jain, J., Jang, A., Ali, A., Jindal, T., Chou, J., Friedlander, T. W., Hoimes, C., Basu, A., Zakharia, Y., Barata, P. C., Bilen, M. A., Emamekhoo, H., Davis, N. B., Shah, S. A., Milowsky, M. I., Gupta, S., Campbell, M. T., Grivas, P., Sonpavde, G. P., Kilari, D., & Alva, A. S. (2021). Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer, . https://doi.org/10.1002/cncr.34057
Koshkin, Vadim S, et al. "Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study." Cancer vol. (2021). doi: https://doi.org/10.1002/cncr.34057
Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2021 Dec 09; doi: 10.1002/cncr.34057. Epub 2021 Dec 09. PMID: 34882781.
Copy Download .nbib Format: NLM
Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy.

Diagnostics (Basel, Switzerland)

Mogensen MB, Hansen ML, Henriksen BM, Axelsen T, Vainer B, Osterlind K, Nielsen MB.
PMID: 28604623
Diagnostics (Basel). 2017 Jun 12;7(2). doi: 10.3390/diagnostics7020035.

Our aim was to investigate whether dynamic contrast-enhanced ultrasound (DCE-US) can detect early changes in perfusion of colorectal liver metastases after initiation of chemotherapy. Newly diagnosed patients with colorectal cancer with liver metastases were enrolled in this explorative prospective...

Cite
Mogensen MB, Hansen ML, Henriksen BM, et al. Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy. Diagnostics (Basel). 2017;7(2)doi: 10.3390/diagnostics7020035.
Mogensen, M. B., Hansen, M. L., Henriksen, B. M., Axelsen, T., Vainer, B., Osterlind, K., & Nielsen, M. B. (2017). Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy. Diagnostics (Basel, Switzerland), 7(2), . https://doi.org/10.3390/diagnostics7020035
Mogensen, Marie Benzon, et al. "Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy." Diagnostics (Basel, Switzerland) vol. 7,2 (2017). doi: https://doi.org/10.3390/diagnostics7020035
Mogensen MB, Hansen ML, Henriksen BM, Axelsen T, Vainer B, Osterlind K, Nielsen MB. Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy. Diagnostics (Basel). 2017 Jun 12;7(2). doi: 10.3390/diagnostics7020035. PMID: 28604623; PMCID: PMC5489955.
Copy Download .nbib Format: NLM
Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma.

Kidney cancer (Clifton, Va.)

Osterman CK, Deal AM, Milowsky MI, Bjurlin MA, Rose TL.
PMID: 33195888
Kidney Cancer. 2020 Sep 16;4(3):131-137. doi: 10.3233/KCA-200089.

BACKGROUND: The treatment landscape for metastatic clear cell renal cell carcinoma (mRCC) is rapidly changing. It is unknown how adoption of new types of therapies may differ by patient age.OBJECTIVE: To compare trends in first-line therapy use for older...

Cite
Osterman CK, Deal AM, Milowsky MI, et al. Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma. Kidney Cancer. 2020;4(3):131-137doi: 10.3233/KCA-200089.
Osterman, C. K., Deal, A. M., Milowsky, M. I., Bjurlin, M. A., & Rose, T. L. (2020). Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma. Kidney cancer (Clifton, Va.), 4(3), 131-137. https://doi.org/10.3233/KCA-200089
Osterman, Chelsea K, et al. "Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma." Kidney cancer (Clifton, Va.) vol. 4,3 (2020): 131-137. doi: https://doi.org/10.3233/KCA-200089
Osterman CK, Deal AM, Milowsky MI, Bjurlin MA, Rose TL. Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma. Kidney Cancer. 2020 Sep 16;4(3):131-137. doi: 10.3233/KCA-200089. PMID: 33195888; PMCID: PMC7605347.
Copy Download .nbib Format: NLM
Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases.

Journal of oncology

Eefsen RL, Van den Eynden GG, Høyer-Hansen G, Brodt P, Laerum OD, Vermeulen PB, Christensen IJ, Wettergren A, Federspiel B, Willemoe GL, Vainer B, Osterlind K, Illemann M.
PMID: 22919385
J Oncol. 2012;2012:907971. doi: 10.1155/2012/907971. Epub 2012 Aug 02.

The purpose of this study was to characterise growth patterns, proteolysis, and angiogenesis in colorectal liver metastases from chemonaive patients with multiple liver metastases. Twenty-four patients were included in the study, resected for a median of 2.6 metastases. The...

Cite
Eefsen RL, Van den Eynden GG, Høyer-Hansen G, et al. Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases. J Oncol. 2012;2012:907971doi: 10.1155/2012/907971.
Eefsen, R. L., Van den Eynden, G. G., Høyer-Hansen, G., Brodt, P., Laerum, O. D., Vermeulen, P. B., Christensen, I. J., Wettergren, A., Federspiel, B., Willemoe, G. L., Vainer, B., Osterlind, K., & Illemann, M. (2012). Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases. Journal of oncology, 2012907971. https://doi.org/10.1155/2012/907971
Eefsen, Rikke Løvendahl, et al. "Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases." Journal of oncology vol. 2012 (2012): 907971. doi: https://doi.org/10.1155/2012/907971
Eefsen RL, Van den Eynden GG, Høyer-Hansen G, Brodt P, Laerum OD, Vermeulen PB, Christensen IJ, Wettergren A, Federspiel B, Willemoe GL, Vainer B, Osterlind K, Illemann M. Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases. J Oncol. 2012;2012:907971. doi: 10.1155/2012/907971. Epub 2012 Aug 02. PMID: 22919385; PMCID: PMC3419438.
Copy Download .nbib Format: NLM
Electrocardiographic Changes During Initiation of Lithium Augmentation of Antidepressant Pharmacotherapy.

Journal of clinical psychopharmacology

Berger M, Kermer J, Behr J, Schulz-Menger J, Bilal S, Osterland SL, O'Malley G, Bschor T, Schlattmann P, Stamm T, Steinacher B, de Millas W, Richter C, Heinz A, Adli M, Buspavanich P, Ricken R.
PMID: 34854829
J Clin Psychopharmacol. 2022 Jan-Feb 01;42(1):87-91. doi: 10.1097/JCP.0000000000001496.

PURPOSE/BACKGROUND: Lithium augmentation of antidepressants represents a common strategy to overcome treatment resistance in patients with major depressive disorder. The use of lithium has been associated with cardiovascular adverse effects such as QTc prolongation and tachyarrhythmia. Although the previous...

Cite
Berger M, Kermer J, Behr J, et al. Electrocardiographic Changes During Initiation of Lithium Augmentation of Antidepressant Pharmacotherapy. J Clin Psychopharmacol. 2022;42(1):87-91doi: 10.1097/JCP.0000000000001496.
Berger, M., Kermer, J., Behr, J., Schulz-Menger, J., Bilal, S., Osterland, S. L., O'Malley, G., Bschor, T., Schlattmann, P., Stamm, T., Steinacher, B., de Millas, W., Richter, C., Heinz, A., Adli, M., Buspavanich, P., & Ricken, R. (2022). Electrocardiographic Changes During Initiation of Lithium Augmentation of Antidepressant Pharmacotherapy. Journal of clinical psychopharmacology, 42(1), 87-91. https://doi.org/10.1097/JCP.0000000000001496
Berger, Maximilian, et al. "Electrocardiographic Changes During Initiation of Lithium Augmentation of Antidepressant Pharmacotherapy." Journal of clinical psychopharmacology vol. 42,1 (2022): 87-91. doi: https://doi.org/10.1097/JCP.0000000000001496
Berger M, Kermer J, Behr J, Schulz-Menger J, Bilal S, Osterland SL, O'Malley G, Bschor T, Schlattmann P, Stamm T, Steinacher B, de Millas W, Richter C, Heinz A, Adli M, Buspavanich P, Ricken R. Electrocardiographic Changes During Initiation of Lithium Augmentation of Antidepressant Pharmacotherapy. J Clin Psychopharmacol. 2022 Jan-Feb 01;42(1):87-91. doi: 10.1097/JCP.0000000000001496. PMID: 34854829.
Copy Download .nbib Format: NLM
Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment.

JCO oncology practice

Osterman CK, Sanoff HK, Wood WA, Fasold M, Lafata JE.
PMID: 34469180
JCO Oncol Pract. 2021 Sep 01;OP2100198. doi: 10.1200/OP.21.00198. Epub 2021 Sep 01.

Emergency department visits and hospitalizations are common among people receiving cancer treatment, accounting for a large proportion of spending in oncology care and negatively affecting quality of life. As oncology care shifts toward value- and quality-based payment models, there...

Cite
Osterman CK, Sanoff HK, Wood WA, et al. Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment. JCO Oncol Pract. 2021;OP2100198doi: 10.1200/OP.21.00198.
Osterman, C. K., Sanoff, H. K., Wood, W. A., Fasold, M., & Lafata, J. E. (2021). Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment. JCO oncology practice, OP2100198. https://doi.org/10.1200/OP.21.00198
Osterman, Chelsea K, et al. "Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment." JCO oncology practice vol. (2021): OP2100198. doi: https://doi.org/10.1200/OP.21.00198
Osterman CK, Sanoff HK, Wood WA, Fasold M, Lafata JE. Predictive Modeling for Adverse Events and Risk Stratification Programs for People Receiving Cancer Treatment. JCO Oncol Pract. 2021 Sep 01;OP2100198. doi: 10.1200/OP.21.00198. Epub 2021 Sep 01. PMID: 34469180.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries